Regulus Therapeutics just finished dosing patients in toxicity studies for its second-generation autosomal dominant polycystic kidney disease (ADPKD) candidate RGLS8429. Based on FDA discussions and data from a Phase Ib trial on original ADPKD candidate RGLS4326, Regulus is shifting away from the first-generation candidate and prioritizing the newer candidate, according to a statement.

BioNova Pharmaceuticals has a couple molecules in early development for blood cancers, but, in an effort to get to the clinic faster, the biotech is doling out $200 million to Sutro Biopharma for some more advanced treatments. The Shanghai biotech will pay an initial $4 million to license the San Francisco-based company’s CD74-targeting antibody-drug conjugate for development […]

Greater Cincinnati is set to welcome another public company. Blue Water Vaccines, a downtown-headquartered biopharma company, filed plans Friday with the Securities and Exchange Commission for an initial public stock offering, or IPO. The move follows three other locally based companies that have already gone public this year, with another local IPO pending. Blue Water […]